July 31, 2018
- Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results
July 24, 2018
- Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from FDA for the Treatment of Patients with Geographic Atrophy
June 26, 2018
- Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™
June 26, 2018
- Apellis Pharmaceuticals Provides Update on Two Phase Ib Trials for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
June 19, 2018
- Apellis Pharmaceuticals to Host R&D Day on June 26, 2018
May 31, 2018
- Apellis Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
April 30, 2018
- Apellis Pharmaceuticals Reports First Quarter 2018 Business Update and Financial Results
April 23, 2018
- Apellis Pharmaceuticals Announces Closing of Offering of Common Stock
April 18, 2018
- Apellis Pharmaceuticals Announces Pricing of Offering of Common Stock
April 16, 2018
- Apellis Pharmaceuticals Announces Proposed Offering of Common Stock
April 16, 2018
- Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab
March 19, 2018
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
February 23, 2018
- Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
February 22, 2018
- Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy
January 2, 2018
- Apellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference